This Week's CGT News: First Treg Therapy Approved
July 7, 2026
First Treg-based cell therapy approved, FDA advanced therapy office faces fresh turnover, and preclinical CAR T studies target rare blood cancers and glioblastoma
5 min read
False
Advertisement
Research News
AI Framework Helps Identify New CAR T Target
July 6, 2026
A human-in-the-loop AI strategy helped narrow more than 10,000 candidates to a CAR T target now validated in mouse models
2 min read
CAR T Cells Target TNF in Mouse Model of Rheumatoid Arthritis
June 30, 2026
A single infusion of engineered T cells degraded soluble TNF and produced durable disease control in mice
2 min read
In Vivo CRISPR Therapy Succeeds in Phase 3 Trial
June 22, 2026
A single infusion of Intellia’s in vivo gene-editing therapy reduced monthly hereditary angioedema attacks by 87 percent
3 min read
Tissue-Resident NK Cells Slow Solid Tumor Growth in Mice
June 16, 2026
The study points to a possible off-the-shelf cell therapy for solid tumors
2 min read
Stem Cells More Cost-Effective than Gene Therapy for Sickle Cell Disease
June 16, 2026
Researchers found gene therapy produced the highest modeled health benefit, but haploidentical stem cell transplantation offered better value at current prices
2 min read
This Week’s Biopharma News: Big Moves in Bispecifics
June 9, 2026
Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody
4 min read
This Week’s CGT News: Promising Data for In Vivo CAR T
June 8, 2026
Legend and Kelonia reveal 100 percent response rates in phase 1 trials, dual CAR T opens doors for kidney transplant patients, and iPDSC therapy beefs up failing hearts
5 min read
This Week’s Biopharma News: New Approvals, Appeals, and AI
June 2, 2026
Datroway and Hepcludex secure notable FDA approvals, while Outlook wins its bevacizumab appeal, BioMarin reports phase 3 VOXZOGO data, and BMS partners with Anthropic
6 min read
